| INTRODUCTION
Viral hepatitis is a leading cause of mortality worldwide, with an estimated 1.45 million attributable deaths in 2013. 1 Chronic hepatitis B and C infections represent the start of a spectrum of disease spanning fibrosis, cirrhosis, decompensation and death. The cumulative incidence of decompensation at 5 years ranges from 7.5% to 15%. [2] [3] [4] Decompensated cirrhosis confers a particularly poor prognosis, with a median survival of less than 2 years. 5 The development of variceal bleeding, ascites and spontaneous bacterial peritonitis are directly related to worsening portal hypertension.
Other than anti-virals and non-selective beta blockers, there are limited medications in routine clinical practice that can reduce risk of liver decompensation. [6] [7] [8] [9] [10] Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, are primarily indicated for dyslipidemia and associated atherosclerotic diseases. Their use in chronic liver disease has attracted attention due to potential anti-viral, anti-inflammatory,
anti-fibrotic and anti-proliferative pleotropic effects. The protective role of statins against hepatocellular carcinoma has been consistently demonstrated in a number of population based studies with a risk reduction of >30%. [11] [12] [13] [14] Statins may also ameliorate intrahepatic vascular tone thus affecting portal hypertension. 15 Clinical correlation in terms of reduction in decompensation events have been recently
shown. In a cohort of chronic hepatitis C infected patients, statins reduced the risk of overall liver decompensation by 45%, and specifically of ascites by 41% and variceal bleeding by 61%. 16 The protective effect of statins in patients with chronic hepatitis B was recently reported in two studies using the same population database, but both suffer from immortal time bias. 17, 18 The objective of our study was to evaluate the association between statin use and risk of liver decompensation and death in an independent population based cohort with chronic viral hepatitis by landmark analysis and propensity score weighting. We hypothesise that statins would confer a protective role against liver decompensation, which if confirmed, would importantly add to the limited treatments currently available for portal hypertension.
2 | ME TH ODS
| Study design and data source
We performed a territory wide retrospective cohort study using the Hospital Authority registry database in Hong Kong, which has a population of over seven million people. 23 The cDDD is the sum of DDD during the exposure period. Patients never exposed to statins or those who started statins after the exposure period (i.e. the landmark date) are designated non-users, as the latter group would have an unexposed period during which they would be at risk for liver decompensation and death. Patients in both groups were followed up to 8 years from the landmark date (considered day 0 for analysis) to evaluate risks of the primary and secondary outcomes ( Figure S1 ). The follow-up duration (years) for landmark analysis cohort was the duration (years) after the landmark date.
b
All biochemical parameters (continuous variables) were transformed by log e to a normal distribution.
via multiple imputations by chained equations to create five complete datasets after 10 iterations. 25, 26 The imputed variables were platelet, total bilirubin, albumin, alanine aminotransferase and creatinine. The frequency of missing values ranged from 17.2% to 32.8%.
The variables included in the imputation models were all baseline covariates in the PS model, treatment status, various outcome measures and their corresponding Nelson-Aalen estimator of the cumulative hazard at the time of event or censoring. 27 Imputed values were constrained within plausible ranges. The balance in the baseline covariates was assessed between statin users and non-users before and after PS weighting by using the absolute standardized differences (ASD), with values below 0.2 indicating good balance. 28 Additional details are provided in Supplementary Materials.
Weighted Cox proportional hazards regression analyses were used to estimate the hazard ratio (HR) of composite liver decompensation events (accounting for death as a competing risk) and death.
To compensate for effects of weights on variances, we used robust (empirical) variance estimates to calculate 95% CIs. 29 The overall ATT (average treatment effect on the treated)-weighted treatment effect estimates and their standard errors were calculated by combining the estimates obtained on each individual multiple imputation dataset using Rubin's rules. 30 Sensitivity analysis was performed for the effect of statins in specific subgroups: >50 year olds, male sex, beta blocker users, and patients with complete laboratory values not requiring imputation. To evaluate for a dose-dependent relationship, the study population was also stratified into quartiles by cDDD statin exposure. Also, a multivariable time-dependent Cox regression analysis (with statin as a time-dependent variable) was carried out, in which only those patients without any missing data were followed up at baseline, and all covariates in the PS model were included in the Cox model for adjustment. The Kaplan-Meier curves were used to estimate the unweighted and weighted cumulative incidence of composite liver decompensation events (again accounting for death as a competing risk) and death. All statistical tests were two-sided with statistical significance taken as P < .05. Data were analysed using SAS 9.3 (SAS Institute Inc., Cary, NC) and R 3. Table 1 .
Before propensity score weighting, statins users were older (60 AE 13 vs 41 AE 17 years old, P < .001), more likely to be men (62% vs 33%, P < .001) with diabetes (39% vs 6%, P < .001), cardiovascular comorbidities (stroke, coronary artery disease and heart failure, P < .001 for all) on multiple related medications (ACE inhibitor/ ARB, beta blockers, diuretics, antiplatelets, anticoagulants, nucleos(t) ide analogues, P < .001 for all), and with higher creatinine Figure S2 shows the boxplot of the propensity scores of statin users and non-users.
| Statin and risk of composite events and death
Initially, the crude incidences of composite liver decompensation events, with death as a competing risk, and death itself were higher in statin users compared to non-users. After propensity score weighting, the mean follow up period in users of statins was 
| Sensitivity analysis
On subgroup analysis, in men, subjects >50 years old, and patients taking beta-blockers, use of statins reduced risk of composite liver decompensation and death. Also, among the 39 703 patients with complete laboratory data not requiring imputation, statin use remained protective against decompensation and death, by a similar degree as the overall cohort (Table 3) . On dose response analysis, we found statin exposure >385 cDDD was associated with 23% reduction in overall death (HR: 0.77; 95% CI: 0.60-1.00, P = .046).
No dose-dependent relationship on composite liver decompensation events was shown, however, the effect was consistent across cDDD subgroups. When a multivariable time-dependent Cox regression analysis was applied to patients with no missing data, use of statin was again associated with fewer composite decompensation events (HR: 0.75; 95% CI: 0.57-0.97, P = .03), and overall death (HR: 0.62; 95% CI: 0.55-0.70, P < .001).
| DISCUSSION
In this propensity score weighted landmark analysis, we demon- enhanced clearance of indocyanine green. 35 And in a nitric oxide independent pathway, statins can also inhibit hepatic stellate cell contraction via RhoA/Rho-kinase. 36 Currently, two studies using the same population based registry from Taiwan have evaluated the effect of statin use in a hepatitis B endemic population. 17, 18 They showed statins reduced the risk of decompensated cirrhosis by 50%-60% compared to non-users, but a number of limitations should be considered. Of note, patients with prior liver decompensation such as ascites and varices were included, and therefore the risk of index decompensation is difficult to interpret. As ascites is the most common form of liver decompensation with an annual incidence rate almost three times than of variceal bleeding, the lack of exclusion of patients with prior ascites could render the reported risk of decompensation in that study imprecise. 36, 37 This is compounded by the lack of measures of liver disease severity, as patients were predominantly identified by diagnostic codes. If hepatic fibrosis was more significant in one of the groups, progression to cirrhosis and decompensation would be expected to be faster. In contrast, we excluded patients with variceal bleeding, ascites and SBP to more accurately define the risk of new onset liver decompensation. Our patients' liver disease severity were also characterised by platelet count, liver enzymes and liver synthetic function tests, which were balanced after propensity score weighing.
As these variables are used to calculate risk scores like APRI and FIB-4, they provide a noninvasive measure of hepatic fibrosis. Also importantly, the earlier study did not perform landmark analysis to baseline characteristics, thus simulating a randomised placebo controlled study. 39 This is particularly important as patients with more advanced liver disease may not be prescribed statins due to concerns for hepatotoxicity, while patients using statins for cardiovascular comorbidities maybe at increased risk for death. 39,40 (6) The protective effects of statin were confirmed using multiple statistical analysis methodologies, including a multivariable time-dependent cox regression analysis, supporting the robustness of our results.
Some limitations of our study should be acknowledged. The severity of underlying liver disease could not be individually determined, as the database did not contain AST values, and APRI and T A B L E 2 Crude incidence rates of liver decompensation events and death among statin users and non-users, and weighted hazard ratios (with 95% confidence intervals) 41 However, simvastatin has been demonstrated to reduce portal hypertension in a 2009 randomised controlled trial. 42 We could not exclude the possibility of patients taking statins prescribed outside this hospital system. This is very unlikely however as medications prescribed through the territory wide public health care system are heavily subsidised. F I G U R E 2 Weighted cumulative incidence of (A) composite liver decompensation events and (B) death at 8 y (2 y landmark analysis for a single multiple imputation dataset) variceal bleeding could have been found with more cases. It was also possible prophylactic banding may have attenuated the portal hypertensive effect of statins, but we do not have such details. We were however able to show use of statins >385 cDDD was associated with fewer overall deaths. While the cause of death could not be ascertained from the registry, mortality among cirrhotics with viral hepatitis was recently confirmed to be predominantly from liver related causes, such as varices and hepatocellular cancer. 43 Our group has recently shown through landmark analysis and propensity score weighting that statin use reduced the risk of liver cancer by over 30% 11 . Statin's chemopreventive effects maybe mediated through cell cycle arrest, induction of apoptosis and inhibition of tumour cell migration. 44, 45 This would suggest the reduction in death observed is likely mediated by fewer decompensation events and hepatocellular carcinoma. Although our database did not specifically capture adverse events associated with statin use, analysis of an expanded cohort by Huang et al showed no autoimmune hepatitis developed over an approximately 4 year follow up period. 46 Our results contribute to the growing evidence that the benefits and safety of statins likely outweigh their potential hepatotoxic effects, and their use in chronic liver disease should not be reflexively avoided. 16, 38, 47, 48 In summary, in a large population based cohort with chronic viral hepatitis, we importantly showed, through landmark analysis and propensity score weighting, use of statins independently reduced the risk of new onset liver decompensation and death. Future prospective studies evaluating the protective effect of individual statin types among patients with other liver disease aetiologies and at progressive stages of chronic liver disease are warranted.
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